The Rainin Foundation envisions a world where no one suffers from Inflammatory Bowel Disease (IBD). We want to achieve a better understanding of how to help patients manage symptoms and improve their lives even before a cure is obtained.
We support novel, high-risk research and challenge investigators to push boundaries. The beginning of an idea is particularly exciting to us because it’s where we can make the greatest impact. Our investments enable researchers to test ideas and gather data to advance the understanding of IBD. Beyond funding, we recognize the importance of dialogue and facilitate collaboration among innovators to move IBD research forward. We also host an annual Innovations Symposium where we invite guest speakers to share the latest IBD research.
Health Program Snapshot
Innovations Symposium
The Foundation’s annual event brings together clinicians, researchers and trainees from around the world to exchange ideas and collaborate to advance IBD research.
Solving IBD
Explore how our investments are advancing cutting-edge ideas, meet the researchers we support, make connections and learn about our future funding directions.
Scientific Advisory Board
This group of leading researchers provides scientific expertise to strengthen our health grantmaking and strategies toward solving IBD.
Health Initiatives
We support bold ideas and initiatives that have the potential to improve the prediction, prevention and treatment of IBD.
Health Grants
We invest early in novel approaches and support collaboration among investigators and across disciplines, believing this can have the greatest impact in IBD research.
Health News & Stories
04/01/2026 | Health
Three exceptional postdoctoral researchers will each receive a $300,000 grant, awarded over two years, to support their innovative biomedical research relevant to IBD.
03/24/2026 | Health
Highlights from our conversation with Gary Mathias of Thetis Pharmaceuticals, a clinical-stage biopharmaceutical company developing alternatives to immuno-suppressive therapies.
03/24/2026 | Health
Explore highlights from our conversation with Julie Saiki, PhD, of Azora Therapeutics, a clinical-stage biopharmaceutical company developing an alternative to immuno-suppressive therapies.
Sign Up For Our Newsletter
Stay updated on the Kenneth Rainin Foundation and our grantees.
